Falling giants and the rise of gene editing: ethics, private interests and the public good

被引:15
作者
Capps, Benjamin [1 ]
Chadwick, Ruth [2 ]
Joly, Yann [3 ]
Mulvihill, John J. [4 ]
Lysaght, Tamra [5 ]
Zwart, Hub [6 ]
机构
[1] Dalhousie Univ, Dept Bioeth, Fac Med, Halifax, NS, Canada
[2] Univ Manchester, Sch Law, Manchester, Lancs, England
[3] McGill Univ, Dept Human Genet, Ctr Genom & Policy, Quebec City, PQ, Canada
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Norman, OK 73019 USA
[5] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Biomed Eth, Singapore, Singapore
[6] Radboud Univ Nijmegen, Dept Philosophy & Sci Studies, Fac Sci, Nijmegen, Netherlands
关键词
Public good; Public interest; CRISPR; Solidarity; Benefit sharing; Ethics in genomic research; Human genome project; Biobank; BIOBANKS; CRISPR; TRUST; LIFE;
D O I
10.1186/s40246-017-0116-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
This paper considers the tensions created in genomic research by public and private for-profit ideals. Our intent is to strengthen the public good at a time when doing science is strongly motivated by market possibilities and opportunities. Focusing on the emergence of gene editing, and in particular CRISPR, we consider how commercialisation encourages hype and hope- a sense that only promise and idealism can achieve progress. At this rate, genomic research reinforces structures that promote, above all else, private interests, but that may attenuate conditions for the public good of science. In the first part, we situate genomics using the aphorism that `on the shoulders of giants we see farther'; these giants are infrastructures and research cultures rather than individual `heroes' of science. In this respect, private initiatives are not the only pivot for successful discovery, and indeed, fascination in those could impinge upon the fundamental role of public-supported discovery. To redress these circumstances, we define the extent to which progress presupposes research strategies that are for the public good. In the second part, we use a `falling giant' narrative to illustrate the risks of over-indulging for-profit initiatives. We therefore offer a counterpoint to commercialised science, using three identifiable `giants'-scientists, publics and cultures-to illustrate how the public good contributes to genomic discovery.
引用
收藏
页数:10
相关论文
共 47 条
[1]  
[Anonymous], 2011, GENOMICS
[2]  
[Anonymous], 2011, SCI MART PRIVATIZING, DOI DOI 10.4159/HARVARD.9780674061132
[3]  
[Anonymous], NEXT GENER SEQ APPL
[4]   Stem cell therapy: hope or hype? Safety and quality must be assured before this treatment can really benefit patients [J].
Braude, P ;
Minger, SL ;
Warwick, RM .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7501) :1159-1160
[5]   The commercialization of genome-editing technologies [J].
Brinegar, Katelyn ;
Yetisen, Ali K. ;
Choi, Sun ;
Vallillo, Emily ;
Ruiz-Esparza, Guillermo U. ;
Prabhakar, Anand M. ;
Khademhosseini, Ali ;
Yun, Seok-Hyun .
CRITICAL REVIEWS IN BIOTECHNOLOGY, 2017, 37 (07) :924-932
[6]  
Capps B., 2014, FUTURE BIOETHICS INT, P235
[7]  
Capps B, 2013, LAW INNOV TECHNOL, V5, P113, DOI DOI 10.5235/17579961.5.1.113
[8]  
Capps B, 2017, ETHICAL RATIONALISM AND THE LAW, P149
[9]   Can a good tree bring forth evil fruit? The funding of medical research by industry [J].
Capps, Benjamin .
BRITISH MEDICAL BULLETIN, 2016, 118 (01) :5-15
[10]   Models of biobanks and implications for reproductive health innovation [J].
Capps, Benjamin .
MONASH BIOETHICS REVIEW, 2015, 33 (04) :238-257